Aggression in children treated with clobazam for epilepsy.

abstract：OBJECTIVES:To evaluate the clinical outcome of Parkinson disease (PD) patients treated with selegiline (with L-Dopa/decarboxylase inhibitor) in the early stage of the disease in comparison with that of late-stage use of selegiline. METHODS:The study and the reference groups were extracted from a large database of the ...

journal_title：Clinical neuropharmacology

authors： Mizuno Y,Kondo T,Kuno S,Nomoto M,Yanagisawa N

更新日期：2010-01-01 00:00:00

abstract：OBJECTIVE:To review the current evidence on the effectiveness of second-generation antipsychotics (SGAs) in the treatment of tardive dystonia (TDt) and give recommendations for treatment. METHODS:Medline/PubMed/Psyclit/Embase database searches were conducted in January 2015, and a manual review of references within th...

journal_title：Clinical neuropharmacology

authors： Pinninti NR,Faden J,Adityanjee A

更新日期：2015-09-01 00:00:00

abstract：:Newly introduced dopamine agonists, such as ropinirole, may offer advantages compared to such older drugs as bromocriptine in patients with advanced Parkinson's disease (PD) with response oscillations or waning efficacy. Dose equivalence of these two drugs, however, has not been well established, which may complicate ...

journal_title：Clinical neuropharmacology

authors： Giménez-Roldán S,Esteban EM,Mateo D

更新日期：2001-11-01 00:00:00

abstract：:The description of multiple classes of opioid receptors has had a major impact on our understanding of the mechanisms of analgesia. Three major classes of opioid receptors have been defined: mu, kappa, and delta. The mu receptors have been further subclassified into two distinct subtypes (mu 1 and mu 2), as have the d...

journal_title：Clinical neuropharmacology

authors： Pasternak GW

更新日期：1993-02-01 00:00:00

abstract：:Studies assessing the effect of transdermal nicotine in Parkinson's disease (PD) have generated mixed results regarding its efficacy to treat motor and cognitive deficits. These studies generally reported good tolerability in nonsmoking PD patients. The authors report the tolerability data of an open trial with transd...

journal_title：Clinical neuropharmacology

authors： Lemay S,Blanchet P,Chouinard S,Masson H,Soland V,Bédard MA

更新日期：2003-09-01 00:00:00

abstract：:Antiepileptic drugs might be effective in the treatment of patients with Posttraumatic Stress Disorder, a condition with unmet pharmacologic needs. We review the literature on the efficacy and tolerability of antiepileptic drugs in Posttraumatic Stress Disorder, both case reports and open studies, as well as controlle...

journal_title：Clinical neuropharmacology

authors： Iancu I,Rosen Y,Moshe K

更新日期：2002-07-01 00:00:00

abstract：ABSTRACT:Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in children and adolescents. Methylphenidate (MPH) is one of the most widely used drugs in the treatment of ADHD. Enuresis can occur comorbidly with ADHD. However, enuresis is sometimes seen in patients with ADHD as an adve...

journal_title：Clinical neuropharmacology

authors： Uzun N,Akinci MA,Karatoprak S

更新日期：2021-01-01 00:00:00

abstract：OBJECTIVES:Obsessive-compulsive disorder (OCD) is notably a comorbid disorder in patients with schizophrenia. This study aimed to evaluate clinical features and correlates of early onset patients with schizophrenia with OCD. METHODS:In the present study, we included 10 patients with both schizophrenia and OCD and 19 p...

journal_title：Clinical neuropharmacology

authors： Baytunca B,Kalyoncu T,Ozel I,Erermiş S,Kayahan B,Öngur D

更新日期：2017-11-01 00:00:00

abstract：:Deprenyl, a selective inhibitor of monoamine oxidase, type B, which is free of the "tyramine effect," may ameliorate symptom fluctuations in advanced Parkinson's disease (PD). We randomized 96 patients with marked symptom fluctuations at three centers to receive either deprenyl 5 mg b.i.d. or placebo in parallel fashi...

journal_title：Clinical neuropharmacology

authors： Golbe LI,Lieberman AN,Muenter MD,Ahlskog JE,Gopinathan G,Neophytides AN,Foo SH,Duvoisin RC

更新日期：1988-02-01 00:00:00

abstract：:Patients with schizophrenia often experience comorbid obsessive-compulsive syndromes (OCSs). Within these patients, a significant subgroup developed secondary OCS during treatment with antiserotonergic, atypical antipsychotic agents such as clozapine. Although cognitive behavioral therapy and antiobsessive antidepress...

journal_title：Clinical neuropharmacology

authors： Englisch S,Esslinger C,Inta D,Weinbrenner A,Peus V,Gutschalk A,Schirmbeck F,Zink M

更新日期：2009-07-01 00:00:00

abstract：:Midazolam, a potent short-acting benzodiazepine, is a safe and highly effective agent for the control of status epilepticus. Its efficacy in the control of neonatal seizures, however, has not been determined. Six neonates (aged 1-9 days; gestation, 30-41 weeks) developed seizures from a variety of causes. In each case...

journal_title：Clinical neuropharmacology

authors： Sheth RD,Buckley DJ,Gutierrez AR,Gingold M,Bodensteiner JB,Penney S

更新日期：1996-04-01 00:00:00

abstract：OBJECTIVE:The use of amobarbital in the Wada test varied between epilepsy centers, with no unified dosing or protocols available in the literature to standardize its use. We aimed to determine the dose of amobarbital in the presurgical evaluations of patients with temporal lobe epilepsy. METHODS:A retrospective study ...

journal_title：Clinical neuropharmacology

authors： Bajammal S,Babtain F,Alqadi K,Baeesa S,Kurdi K,Madani N,Al Said Y

更新日期：2020-11-01 00:00:00

abstract：:Flumazenil is a benzodiazepine receptor antagonist. It is currently used mainly in the anaesthetic and emergency rooms to reverse the effect of exogenous benzodiazepines. Its use in a variety of experimental animal models and in human neuropsychiatric disorders continues to generate a wealth of information on the poss...

journal_title：Clinical neuropharmacology

authors： Malizia AL,Nutt DJ

更新日期：1995-06-01 00:00:00

abstract：:Monoamine oxidase type B (MAO-B) is the predominant isoform responsible for the metabolic breakdown of dopamine in the brain. Selective inhibition of brain MAO-B results in elevation of synaptosomal dopamine concentrations. Data have been reported regarding the selective MAO-B inhibitors, rasagiline and selegiline, fo...

journal_title：Clinical neuropharmacology

authors： Fernandez HH,Chen JJ

更新日期：2007-05-01 00:00:00

abstract：:We describe a 78-year-old gentleman who, following bilateral above-knee amputations, developed symptoms of restless legs syndrome in the absent portions of his lower extremities. These symptoms improved with dopamine agonist therapy. In addition, he later developed parkinsonism with prominent rest tremor on metoclopra...

journal_title：Clinical neuropharmacology

authors： Hanna PA,Kumar S,Walters AS

更新日期：2004-03-01 00:00:00

abstract：BACKGROUND:Recent studies indicate that the traditional Japanese herbal medicine yi-gan san (YGS, yokukan-san in Japanese) may be safe and useful for treating behavioral and psychological symptoms in dementia, borderline personality disorder, neuroleptic-induced tardive dyskinesia, and treatment-resistant schizophrenia...

journal_title：Clinical neuropharmacology

authors： Miyaoka T,Furuya M,Kristian L,Wake R,Kawakami K,Nagahama M,Kawano K,Ieda M,Tsuchie K,Horiguchi J

更新日期：2011-01-01 00:00:00

abstract：RATIONALE:Clobazam (CLB) has proven efficacy against multiple seizure types. Although available in many countries, it is not approved by the US Food and Drug Administration. The objective of this study was to evaluate the usage patterns, efficacy, tolerability, and 1-year retention of CLB in patients with refractory ep...

journal_title：Clinical neuropharmacology

authors： Montenegro MA,Arif H,Nahm EA,Resor SR Jr,Hirsch LJ

更新日期：2008-11-01 00:00:00

abstract：OBJECTIVES:The units of different botulinum toxin products are not identical, and the dose equivalence has been debated for several years. In the year 2000, our clinic changed the recommended botulinum toxin product from Botox to Dysport for the treatment of cervical dystonia. Based on published reports, where dose con...

journal_title：Clinical neuropharmacology

authors： Rystedt A,Nyholm D,Naver H

更新日期：2012-11-01 00:00:00

abstract：:The pyrimidine nucleosides uridine (URI) and cytidine (CYT), alone or associated with n-acetyl-glutamine (NAG), were injected acutely or subchronically to aged (26 months old) male rats of the Sprague-Dawley strain. Learning and memory abilities of the animals were studied with tests of avoidance behavior. The acquisi...

journal_title：Clinical neuropharmacology

authors： Drago F,D'Agata V,Valerio C,Spadaro F,Raffaele R,Nardo L,Grassi M,Freni V

更新日期：1990-08-01 00:00:00

abstract：OBJECTIVES:Treatment-resistant depression is a common occurrence in clinical practice as well as combination treatment with 2 different antidepressants. In the present case series, we study the effectiveness of the addition of reboxetine, during 12 weeks, to 14 outpatients diagnosed with major depressive disorder, acco...

journal_title：Clinical neuropharmacology

authors： López-Muñoz F,Rubio G,Alamo C,García-García P,Pardo A

更新日期：2006-07-01 00:00:00

abstract：:Drugs (e.g., PCP) which interfere with glutamatergic transmission at the N-methyl D-aspartate (NMDA) subclass of glutamate receptors precipitate both positive and negative symptoms of psychosis in humans. Based on a proposed "glutamatergic deficiency" in schizophrenia, pharmacologic facilitation of NMDA-mediated neura...

journal_title：Clinical neuropharmacology

authors： Rosse RB,Schwartz BL,Davis RE,Deutsch SI

更新日期：1991-06-01 00:00:00

abstract：:During long-term treatment of schizophrenia with antipsychotic medication, side effects such as weight gain and tardive dyskinesia may develop, while other extrapyramidal side effects may continue. A large multicenter, double-blind, comparative trial of haloperidol decanoate and fluphenazine decanoate has been complet...

journal_title：Clinical neuropharmacology

authors： Cookson JC

更新日期：1991-01-01 00:00:00

abstract：:Four to 10% of patients with Parkinson disease and chronically treated with levodopa undergo an addictionlike behavioral disturbance named dopamine dysregulation syndrome (DDS). This article suggests that patients with Parkinson disease could be especially prone to develop DDS due to the dopamine deficiency and the "p...

journal_title：Clinical neuropharmacology

authors： Linazasoro G

更新日期：2009-01-01 00:00:00

abstract：:Monoamine oxidase (MAO) inhibitors (MAOIs) provide effective alternative therapy for those patients with major depression who do not respond to tricyclic antidepressants or such related compounds as the selective serotonin reuptake inhibitors. This article reviews studies on the efficacy of both the classical MAOIs an...

journal_title：Clinical neuropharmacology

authors： Nolen WA,Hoencamp E,Bouvy PF,Haffmans PM

更新日期：1993-01-01 00:00:00

abstract：OBJECTIVE:Neuroleptic malignant syndrome was induced by aripiprazole in a 12 1/2-year-old boy. The patient had a history of reactive airway disease, pervasive developmental disorder, and learning disability. METHOD:The patient was interviewed and examined, and additional history was taken from the medical records. The...

journal_title：Clinical neuropharmacology

authors： Palakurthi HB,Parvin MM,Kaplan S

更新日期：2007-01-01 00:00:00

abstract：:Recent studies have suggested that deprenyl may exert a neuroprotective influence and thus retard progression of Parkinson's disease (PD). On the other hand, the data do not disprove that deprenyl is primarily another form of symptomatic therapy like levodopa. Longitudinal Gompertzian analysis demonstrates the absence...

journal_title：Clinical neuropharmacology

authors： Riggs JE

更新日期：1991-12-01 00:00:00

abstract：:The effects of carbamazepine (CBZ) on spontaneous secretion of prolactin (PRL) and after stimulation with thyrotropin releasing hormone (TRH) were evaluated. Volunteer subjects after acute CBZ administration, and epileptic subjects with complex partial seizures chronically treated with CBZ, were examined. In an epilep...

journal_title：Clinical neuropharmacology

authors： Bonuccelli U,Murialdo G,Martino E,Lecchini S,Bonura ML,Bambini G,Murri L

更新日期：1985-01-01 00:00:00

abstract：:The long-term effects of mesulergine, a new drug with dopamine agonistic properties, were studied in 28 patients with Parkinson's disease. In 18 patients with late side effects of levodopa, the addition of mesulergine (10.9 mg/day) induced significant decreases in the global (-48%), rigidity (-62%), and akinesia (-37%...

journal_title：Clinical neuropharmacology

authors： Rascol A,Montastruc JL,Rascol O,Senard JM

更新日期：1986-01-01 00:00:00

abstract：:trans-Dihydrolisuride, a partial dopamine receptor agonist, was tested for its effects on chorea in a double-blind, crossover clinical study in 10 patients with Huntington's disease. In eight patients, a neurophysiological evaluation was also performed. No reduction in choreic movements or improvement in voluntary mov...

journal_title：Clinical neuropharmacology

authors： Stocchi F,Carta A,Berardelli A,Antonini A,Argenta M,Formica A,Agnoli A

更新日期：1989-10-01 00:00:00

abstract：:A case of a mentally retarded patient with sporadic paroxysmal dystonia, unresponsive to anticonvulsant therapy, is described. He had a long-standing history of neuroleptic drug intake. Trihexyphenidyl in a total daily dosage of 20 mg totally suppressed the crises. ...

journal_title：Clinical neuropharmacology

authors： Micheli F,Fernandez Pardal M,de Arbelaiz R,Lehkuniec E,Giannaula R

更新日期：1987-08-01 00:00:00